

REMARKS/ARGUMENTS

By the present amendment, claims 17-20 are pending in this application. Claims 1-16 are canceled herein without prejudice. Claims 21-88 were previously withdrawn as being directed to non-elected subject matter. Applicants reserve the right to file one or more continuation, continuation-in-part, or divisional applications towards any canceled or withdrawn subject matter. Claims 17-20 are amended herein. Basis for these amendments may be found throughout the specification and claims as originally filed. For example, basis for the amendments in claim 17 may be found in claims 13 and 16 as originally filed. Other amendments provide the correct claim dependencies. No new matter has been added.

Claim Objections

Claim 17 is objected to for reciting the word "which" in line 1, that should be replaced with the word "further" to be grammatically correct. As amended herein, claim 17 now recites the word "further."

Claim 17 is objected to as being dependent upon a rejected base claim, i.e. claim dependent 16 and independent claim 13, but would be allowable if rewritten in independent form including all the limitations of the base claim and any intervening claims.

As amended herein, claim 17 is written in independent form and includes all the limitations of base claim 13 and intervening claim 16. Dependent claims 18-20 have also been amended to be dependent from independent claim 17. Applicants respectfully request reconsideration and allowance of claims 17-20.

Claim Rejections - 35 U.S.C. §102

Claims 1-16 and 18-20 are rejected under 35 U.S.C. §102(b) as allegedly being anticipated by Nakayama et al. (1999, PNAS, Vol. 96, pgs. 8991-8996) as evidenced by Xing et al. (1989, Immunol. Cell Biol., Vol. 67, pgs. 183-195).

While not necessarily agreeing with the characterization of claims 1-16 and 18-20, but in order to further prosecution of this application to grant of a U.S. patent, claims 1-16 have been canceled, and claims 18-20 have been amended to be dependent from allowed

independent claim 17. As such, claims 18-20 now include all the limitations of allowed claim 17. Therefore, as amended herein, claims 18-20 are not anticipated by the cited references. Applicants respectfully request reconsideration and removal of this rejection.

Claim Rejections - 35 U.S.C. §112

Claims 7 and 10 are rejected under 35 U.S.C. §112, second paragraph as allegedly being indefinite for reciting the phrase "wherein the O-glycan" in line 1, which allegedly lacks antecedent basis in these claims.

As amended herein, claims 7 and 10 have been canceled, which renders the rejection of these claims moot. Applicants respectfully request reconsideration and removal of this rejection.

CONCLUSION


In view of the above amendments and remarks, reconsideration and favorable action on all claims are respectfully requested. In the event any matters remain to be resolved, the Examiner is requested to contact the undersigned at the telephone number given below so that a prompt disposition of this application can be achieved.

A petition for a one month extension of time under 37 C.F.R. §1.136(a) accompanies this response. The Commissioner is hereby authorized to charge the amount of \$65.00 as payment for the one-month extension of time to Deposit Account No. 07-1896, referencing the above-identified Attorney Docket Number.

No additional fees are believed to be due with the present communication, however, the Commissioner is hereby authorized to charge any additional fees that may be due in connection with the filing of this paper, or credit any overpayment to Deposit Account No. 07-1896, referencing the above-identified Attorney Docket Number.

Respectfully submitted,

Date: March 12, 2010

for  43,049
Lisa A. Haile, J.D., Ph.D.
Registration No.: 38,347
Telephone: (858) 677-1456
Facsimile: (858) 677-1465

DLA PIPER LLP (US)
4365 Executive Drive, Suite 1100
San Diego, California 92121-2133
USPTO Customer No.: 28213